NEW YORK (GenomeWeb News) – Myriad Genetics announced after the close of the market on Thursday an agreement with Pharma Mar to conduct BRCA1 and BRCA2 testing on patients enrolled in a clinical study for the drug firm's novel drug candidate.

Under the agreement, Myriad will conduct testing for patients in a Phase II clinical study for Pharma Mar's PM1183 drug candidate, which induces double-stranded DNA break to cause cell death. Myriad will evaluate BRCA status in patients who respond to the drug candidate.

Financial and other terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.